Investor Flags Antibiotics Co. Melinta's $75M Stock Sale
A stockholder filed a proposed class action in Delaware Chancery Court claiming antibiotics company Melinta Therapeutics Inc.'s board breached its fiduciary duty by entering into an agreement to sell $75 million...To view the full article, register now.
Already a subscriber? Click here to view full article